Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

SANCUSO® (granisetron transdermal system) additional resources

Patient story: Tracy

I was pleasantly surprised by my response to SANCUSO with the control I had for my nausea and vomiting.”

- Tracy

Actual patient

Read how one patient found relief from chemotherapy-induced nausea and vomiting (CINV) with SANCUSO® (granisetron transdermal system) while fighting breast cancer.

Discussion Guide

Download

A discussion tool for nurses and their patients

Download

Patient Brochure

Download

An easy-to-understand introduction to CINV and how SANCUSO can prevent it for patients

Download

Request a sample

You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.

Request Sample

Connect to stay informed

You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.

Stay Informed
Indication and Important Safety Information

Indication

SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.

Important Safety Information

Contraindications

SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Warnings and Precautions

Adverse Reactions

The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).

To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-SANCUSO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information for SANCUSO.